Single-chain analog of human relaxin-2 B-chain that retains antifibrotic, vasodilatory, and cardioprotective effects with minimal cAMP signaling. Easier to produce than native relaxin.
Quickstart Highlights
- Dosage: Investigational
- Frequency: Investigational
- Administration: Subcutaneous
- Cycle length: Investigational
How This Works
Mechanism of Action
How B7-33 Works in Your Body
Peptide Administered
Enters the bloodstream via injection
Receptor Binding
Finds and activates its target receptor
Signal Cascade
Triggers a chain of cellular responses
Biological Effect
The body produces the desired outcome
Benefits & Side Effects
Potential Benefits
- Antifibrotic
- Vasodilation
- Cardioprotection
- Relaxin-like effects
Quick notes
Investigational antifibrotic and cardioprotective agent. Not approved.
References
Community Insights
Summarised from 1 sourceSingle-chain analog of human relaxin-2 B-chain that retains antifibrotic, vasodilatory, and cardioprotective effects with minimal cAMP signaling. Easier to produce than native relaxin. Investigational antifibrotic and cardioprotective agent. Not approved.
Common Dosages Reported
- Investigational Investigational
- Standard protocol dosing
Side Effects Mentioned
- Generally mild, individual variation expected
- See full guide for detailed safety info
Stacking Suggestions
- Consult research and healthcare provider before stacking
What people are saying
Results vary based on individual response
Consistent dosing and timing important
Reviews & Discussion
Real experiences shared by the community — not medical advice.
B7-33 for Fibrosis and Calf Tightness
A user reported significant issues with scar tissue and exercise-induced compartment syndrome in their calves for over 25 years. They have ordered B7-33 with the intent to treat fibrosis and muscle tightness that limits their ability to run.
B7-33 Overview and Classification
Nelson Vergel provided a comprehensive list of peptides, classifying B7-33 as a research-grade peptide primarily used for treating organ fibrosis and promoting tissue repair. The guide notes that B7-33 is a functional agonist of the RXFP1 receptor, intended to mimic the effects of human relaxin 2 with reduced risk of adverse effects.
Interest in B7-33 for cardiac fibrosis and heart failure
A 22-year-old former athlete with myocardial fibrosis and heart failure expressed interest in using B7-33 as a potential treatment to reverse cardiac scarring. They are looking for peptides that specifically target the RXFP1 receptor to manage dilated cardiomyopathy and PVCs.
B7-33 potential for lung inflammation and heart disease
A forum member highlighted research suggesting that B7-33, a single-chain derivative of the relaxin hormone, shows promise for treating lung inflammation and heart disease. They discussed its role as a selective agonist of the RXFP1 receptor and its potential to reduce organ scarring.
B7-33 for muscle or lymph fibrosis inquiry
A user inquired about the efficacy of B7-33 for treating muscle or lymph node fibrosis. They noted that the peptide is gaining interest for its potential anti-fibrotic properties, though they sought more specific biological evidence for these particular applications.
No discussion yet — be the first.
No notes yet — be the first.